Evonetix has completed a $24 million financing round, extending its total series B funding to over $54 million.
The fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also participating in the round.
The investment will enable the continued development of Evonetix’s semiconductor chips to commercial scale, and the extension of gene assembly capabilities for its binary assembly technology to deliver accurate, gene-length DNA in a benchtop instrument.
Colin McCracken, Chief Executive Officer at Evonetix, commented: “Evonetix is in a very exciting phase, having recently opened our early access program. This investment will support us as we execute on our commercial strategy to put benchtop gene synthesis in the hands of users.”
Evonetix’s synthesis process uses a silicon chip to control the synthesis of DNA at thousands of independent thermally controlled reaction sites, or ‘pixels’, and their assembly into accurate long DNA on the chip surface through the company’s patented Binary Assembly process.
This approach is designed to enable the accurate synthesis of thousands of sequences on a single chip to meet the demand for complex libraries and assembly of long DNA in days rather than weeks, accelerating research across the field of synthetic biology.
